Our Partners

Partnerships for vaccines and global health

Our status as an international organization allows IVI to work with diverse groups from public health, government, academia, and industry. As a “neutral broker,” IVI can engage with and bridge public- and private-sector partners in the common goal of making vaccines accessible and available for low-income countries. The following describes the diversity and breadth of our partners.


IVI is headquartered in Seoul, Korea, IVI’s host country. Over the past decade, Korea’s life sciences industry has grown due to strong government support towards R&D and increased investment in research by Korean pharmaceutical companies. The Korean government put forward a strategic industry plan in 2012 that aims to help the country become one of the global top seven drug powerhouses by 2020, and there are similar aspirations for vaccines. Korea’s life sciences industry is projected to grow with the pharmaceutical and biotech industry likely to become one of the fastest growing industry sectors.

Against this backdrop, IVI works with Korean companies, universities, research institutes and government.  We are an international cooperation partner of the Ministry of Health and Ministry of Foreign Affairs, and we work with the Korea National Institute of Health (KNIH), Korea Centers for Disease Control and Prevention (KCDC), and the Korea International Cooperation Agency (KOICA).

We work closely with academia and research institutes. A major partner is Seoul National University (SNU).  Our headquarters is located on the SNU campus, and we have several research and academic collaborations with the university. In addition to SNU, we collaborate with other universities and research institutes such as Korea University, POSTECH, Korea Research Institute of Bioscience and Biotechnology (KRIBB) and Institut Pasteur Korea.

Finally we collaborate with industry, and we are partnering with SK Chemicals and EuBiologics for the development of typhoid and cholera vaccines respectively. In addition, we partner with companies such as Samsung, LG Electronics and Kia Motors.


In the Asia-Pacific region, IVI has become a driver for technology transfer and vaccine R&D. We have established partnerships with six vaccine manufacturers in five countries, in which we transfer technology and work with them on developing vaccines for licensure and/or WHO prequalification.

We are also a member of the Developing Countries Vaccine Manufacturer Network (DCVMN).


Manufacturer Country Vaccine Partnership
SK Chemicals Korea Vi-DT typhoid conjugate vaccine
EuBiologics Korea Inactivated bivalent oral cholera vaccine (Euvichol)
PT BioFarma Indonesia Vi-DT typhoid conjugate vaccine
Incepta Vaccine Ltd. Bangladesh Inactivated bivalent oral cholera vaccine (Cholvax)

Vi-DT typhoid conjugate vaccine

VaBiotech Vietnam Inactivated bivalent oral cholera vaccine (mORC-VAX)
Shantha Biotechnics India Inactivated bivalent oral cholera vaccine (Shanchol)


We also collaborate with public health research organizations in the region. Partners include icddr,b in Bangladesh; National Institute of Cholera and Enteric Diseases (NICED) in India; and National Institute of Hygiene and Epidemiology (NIHE) in Vietnam.

Around the world

IVI is present in Africa and the Americas. We establish and manage field sites, implement research projects, and provide technical assistance and support in countries in these regions in collaboration with local partners.

In sub-Saharan Africa, we established and managed a standardized surveillance network for typhoid and Salmonella infections consisting of field sites in 10 countries (Ghana, Kenya, Sudan, Madagascar, South Africa, Guinea Bissau, Tanzania, Senegal, Ethiopia, and Burkina Faso). This typhoid surveillance network was the first of its kind in Africa and paves the way for a multi-disease surveillance platform to assess other febrile illnesses (e.g., dengue).

Global presence

Our status as an international organization allows us to enter into agreements with other international organizations or nation states. Currently, IVI has 35 countries and the WHO as signatories on our treaty. Several of these countries are where IVI is active and have government support and research partners on the ground (e.g, India, Vietnam, and Nepal). Korea and Sweden are major partners of IVI.

We also engage and collaborate with WHO and Gavi, the Vaccine Alliance on vaccine advocacy, access and policy issues, particularly for the vaccines that we work on (cholera, typhoid, and dengue).